Brief: Nanorepro Receives Special Approval For SARS-CoV-2 Antigen Rapid Test
12/03/2021 14:53
March 12 (Reuters) - NANOREPRO AG NN6G.DE :
* RECEIVES SPECIAL APPROVAL FROM THE BFARM FOR NANOREPRO
SARS-COV-2 ANTIGEN RAPID TEST (VIROMED)
Source text for Eikon: ID:nEQ5GZ9pZa
Further company coverage: NN6G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on NanoRepro AG
See all newsBrief: NanoRepro Enters Market For Diabetes Diagnostics
Brief: NanoRepro FY Profit After Taxes At EUR 29.7 Mln
Brief: Nanorepro Announces Talks With Viromed Group On Integration Of Individual Business Units Terminated For The Time Being
Brief: NanoRepro Completes Comparative Study, Says Its Tests Detect Omicron
Brief: NanoRepro - Change In Forecast 2021 And Outlook 2022 With Dividend